Published in J Exp Med on May 02, 2011
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell (2012) 4.41
The molecular basis of T cell acute lymphoblastic leukemia. J Clin Invest (2012) 3.09
BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood (2012) 2.91
Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood (2013) 2.34
Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet (2011) 2.32
Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. Blood (2012) 2.09
Genetic loss of SH2B3 in acute lymphoblastic leukemia. Blood (2013) 1.87
RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer. Nature (2014) 1.84
Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood (2012) 1.78
Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia. Blood (2012) 1.66
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med (2012) 1.65
CoMEt: a statistical approach to identify combinations of mutually exclusive alterations in cancer. Genome Biol (2015) 1.64
Elevated epidermal thymic stromal lymphopoietin levels establish an antitumor environment in the skin. Cancer Cell (2012) 1.54
Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein. Blood (2015) 1.52
Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21. Proc Natl Acad Sci U S A (2012) 1.46
Molecular genetics of B-precursor acute lymphoblastic leukemia. J Clin Invest (2012) 1.38
Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. Oncotarget (2012) 1.34
High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. J Exp Med (2011) 1.31
Comprehensive analysis of transcriptome variation uncovers known and novel driver events in T-cell acute lymphoblastic leukemia. PLoS Genet (2013) 1.29
Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood (2015) 1.26
Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies. Paediatr Drugs (2012) 1.22
Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. PLoS One (2012) 1.21
Genomic characterization of childhood acute lymphoblastic leukemia. Semin Hematol (2013) 1.19
Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine. Blood (2015) 1.19
Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Cancer Cell (2015) 1.10
Mutational spectrum of adult T-ALL. Oncotarget (2015) 1.09
Transcription factor networks in B-cell differentiation link development to acute lymphoid leukemia. Blood (2015) 1.08
IL-7 in human health and disease. Semin Immunol (2012) 1.08
Structural reorganization of the interleukin-7 signaling complex. Proc Natl Acad Sci U S A (2012) 1.06
NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia. Haematologica (2013) 1.06
The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse. Haematologica (2014) 1.00
The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nat Rev Cancer (2016) 1.00
Interleukin-7 receptor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors with multipotent potential. J Exp Med (2014) 0.99
The role of STAT5 in lymphocyte development and transformation. Curr Opin Immunol (2012) 0.98
Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood (2016) 0.98
Immunotherapy targets in pediatric cancer. Front Oncol (2012) 0.97
Differences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2. Blood (2012) 0.97
Analysis of acquired mutations in transgenes arising in Ba/F3 transformation assays: findings and recommendations. Oncotarget (2017) 0.97
Genomic profiling of B-progenitor acute lymphoblastic leukemia. Best Pract Res Clin Haematol (2011) 0.95
Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia. Cancer Cell (2016) 0.93
Common gamma chain cytokines in combinatorial immune strategies against cancer. Immunol Lett (2015) 0.91
ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling. Nat Commun (2015) 0.91
PAX5 is a tumor suppressor in mouse mutagenesis models of acute lymphoblastic leukemia. Blood (2015) 0.91
Small sizes and indolent evolutionary dynamics challenge the potential role of P2RY8-CRLF2-harboring clones as main relapse-driving force in childhood ALL. Blood (2012) 0.91
Structural insights into the common γ-chain family of cytokines and receptors from the interleukin-7 pathway. Immunol Rev (2012) 0.91
Genetic and epigenetic studies offer new therapeutic options for the treatment of T-cell acute lymphoblastic leukemia. Haematologica (2012) 0.90
Understanding the biology of CRLF2-overexpressing acute lymphoblastic leukemia. Crit Rev Oncog (2011) 0.90
Diagnosis and subclassification of acute lymphoblastic leukemia. Mediterr J Hematol Infect Dis (2014) 0.88
The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia. Leukemia (2015) 0.88
The importance of TSLP in allergic disease and its role as a potential therapeutic target. Expert Rev Clin Immunol (2014) 0.86
IL-7Rα deficiency in p53null mice exacerbates thymocyte telomere erosion and lymphomagenesis. Cell Death Differ (2012) 0.86
Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia. Blood (2015) 0.86
Thymic stromal lymphopoietin and cancer. J Immunol (2014) 0.84
Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies. Leuk Lymphoma (2014) 0.84
JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications. Haematologica (2015) 0.81
Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia/lymphoma. Oncotarget (2016) 0.80
Structural basis of the proinflammatory signaling complex mediated by TSLP. Nat Struct Mol Biol (2014) 0.80
Deep targeted sequencing in pediatric acute lymphoblastic leukemia unveils distinct mutational patterns between genetic subtypes and novel relapse-associated genes. Oncotarget (2016) 0.79
RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications. Haematologica (2016) 0.79
Interleukin-18 produced by bone marrow-derived stromal cells supports T-cell acute leukaemia progression. EMBO Mol Med (2014) 0.79
MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia. Leukemia (2016) 0.79
Stem and progenitor cell dysfunction in human trisomies. EMBO Rep (2014) 0.79
Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell acute lymphoblastic leukaemia. Br J Haematol (2014) 0.78
The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome. Leukemia (2016) 0.78
LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors. J Clin Invest (2016) 0.77
CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia. Oncotarget (2016) 0.77
The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I. Clin Cancer Res (2015) 0.77
Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment. Blood (2016) 0.76
Structural modeling of JAK1 mutations in T-cell acute lymphoblastic leukemia reveals a second contact site between pseudokinase and kinase domains. Haematologica (2016) 0.76
IGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias. PLoS One (2016) 0.76
Effects of p38α/β inhibition on acute lymphoblastic leukemia proliferation and survival in vivo. Leukemia (2015) 0.76
Co-existence of IL7R high and SH2B3 low expression distinguishes a novel high-risk acute lymphoblastic leukemia with Ikaros dysfunction. Oncotarget (2016) 0.76
The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet (2017) 0.75
Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood (2017) 0.75
On mice and humans: the role of thymic stromal lymphopoietin in human B-cell development and leukemia. Haematologica (2016) 0.75
Identification of a genetically defined ultra-high-risk group in relapsed pediatric T-lymphoblastic leukemia. Blood Cancer J (2017) 0.75
JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics. Mol Cell Endocrinol (2017) 0.75
IL-7 Induces an Epitope Masking of γc Protein in IL-7 Receptor Signaling Complex. Mediators Inflamm (2017) 0.75
Y-box-binding protein 1 contributes to IL-7-mediated survival signaling in B-cell precursor acute lymphoblastic leukemia. Oncol Lett (2016) 0.75
Characterisation of the Genomic Landscape of CRLF2-rearranged Acute Lymphoblastic Leukemia. Genes Chromosomes Cancer (2016) 0.75
Interleukin-7 receptor-α gene mutations are not detected in adult T-cell acute lymphoblastic leukemia. Cancer Med (2014) 0.75
High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica (2013) 0.75
The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia. Haematologica (2016) 0.75
Association of interleukin 7 receptor (rs1494555 and rs6897932) gene polymorphisms with asthma in a north Indian population. Allergy Rhinol (Providence) (2015) 0.75
Targetable kinase gene fusions in high risk B-ALL: a study from the Children's Oncology Group. Blood (2017) 0.75
Genomic and transcriptional landscape of P2RY8-CRLF2-positive childhood acute lymphoblastic leukemia. Leukemia (2016) 0.75
Limitations of the 'ambush hypothesis' at the single-gene scale: what codon biases are to blame? Mol Genet Genomics (2014) 0.75
Aberrant Signaling Pathways in T-Cell Acute Lymphoblastic Leukemia. Int J Mol Sci (2017) 0.75
Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia. Br J Cancer (2017) 0.75
Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J Exp Med (1994) 8.97
Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature (2010) 8.48
Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor. Science (1993) 5.22
TSLP: an epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation. Annu Rev Immunol (2007) 4.39
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet (2009) 4.35
Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat Genet (1998) 4.32
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet (2008) 3.69
Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood (2009) 3.50
Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med (2008) 3.24
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 2.54
Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood (2008) 2.41
Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial. Blood (2010) 2.25
Personalized medicine and inhibition of EGFR signaling in lung cancer. N Engl J Med (2009) 2.10
Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J Exp Med (2011) 2.04
Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain. Proc Natl Acad Sci U S A (2001) 2.00
The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. Leukemia (2010) 1.56
Mining for JAK-STAT mutations in cancer. Trends Biochem Sci (2008) 1.52
Thymic stromal lymphopoietin-mediated STAT5 phosphorylation via kinases JAK1 and JAK2 reveals a key difference from IL-7-induced signaling. Proc Natl Acad Sci U S A (2010) 1.50
Active conformation of the erythropoietin receptor: random and cysteine-scanning mutagenesis of the extracellular juxtamembrane and transmembrane domains. J Biol Chem (2006) 1.37
Activating mutation in the TSLPR gene in B-cell precursor lymphoblastic leukemia. Leukemia (2009) 1.33
Interleukin-7 is a growth factor of precursor B and T acute lymphoblastic leukemia. Blood (1990) 1.08
Leukaemia -- a developmental perspective. Br J Haematol (2004) 0.97
ALL-associated JAK1 mutations confer hypersensitivity to the antiproliferative effect of type I interferon. Blood (2010) 0.90
Co-existence of multiple subclones in TEL-AML1 at diagnosis of acute lymphoblastic leukaemia in association with submicroscopic deletion of AML1. Br J Haematol (2005) 0.82
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol (2003) 17.67
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature (2012) 10.99
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature (2008) 10.73
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
Balancing acts: molecular control of mammalian iron metabolism. Cell (2004) 7.82
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell (2012) 6.71
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest (2006) 6.61
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med (2007) 6.55
Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell (2012) 6.07
Two to tango: regulation of Mammalian iron metabolism. Cell (2010) 5.45
Nonsense-mediated decay approaches the clinic. Nat Genet (2004) 5.12
The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell (2011) 5.06
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol (2009) 4.89
Dissecting the genomic complexity underlying medulloblastoma. Nature (2012) 4.77
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet (2009) 4.35
A randomized controlled trial of preoperative intra-aortic balloon pump in coronary patients with poor left ventricular function undergoing coronary artery bypass surgery*. Crit Care Med (2013) 4.10
Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol (2010) 4.09
The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med (2007) 4.04
Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med (2008) 3.98
A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet (2007) 3.94
Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity (2010) 3.88
A sensitive array for microRNA expression profiling (miChip) based on locked nucleic acids (LNA). RNA (2006) 3.71
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet (2008) 3.69
Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol (2009) 3.47
STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood (2006) 3.38
FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. J Clin Oncol (2011) 3.33
Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med (2008) 3.24
BLUEPRINT to decode the epigenetic signature written in blood. Nat Biotechnol (2012) 3.24
Y14 and hUpf3b form an NMD-activating complex. Mol Cell (2003) 3.17
Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell (2011) 3.11
Role of TAZ as mediator of Wnt signaling. Cell (2012) 3.05
Exon-junction complex components specify distinct routes of nonsense-mediated mRNA decay with differential cofactor requirements. Mol Cell (2005) 2.79
In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell (2008) 2.78
Stem cells in severe infantile spinal muscular atrophy (SMA1). Neuromuscul Disord (2012) 2.78
Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol (2005) 2.75
3' end mRNA processing: molecular mechanisms and implications for health and disease. EMBO J (2008) 2.67
Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nat Med (2013) 2.67
Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol (2010) 2.53
Interactions between UPF1, eRFs, PABP and the exon junction complex suggest an integrated model for mammalian NMD pathways. EMBO J (2008) 2.52
Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nat Genet (2010) 2.47
Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood (2007) 2.46
Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet (2002) 2.46
SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors. Nature (2012) 2.46
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet (2013) 2.42
Acquisition of genome-wide copy number alterations in monozygotic twins with acute lymphoblastic leukemia. Blood (2010) 2.38
Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87. J Clin Oncol (2005) 2.36
Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. Blood (2007) 2.31
The liver-specific microRNA miR-122 controls systemic iron homeostasis in mice. J Clin Invest (2011) 2.30
Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol (2012) 2.29
Molecular staging of intracranial ependymoma in children and adults. J Clin Oncol (2010) 2.27
Cross-linking of the mannose receptor on monocyte-derived dendritic cells activates an anti-inflammatory immunosuppressive program. J Immunol (2003) 2.24
A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. Am J Hum Genet (2002) 2.24
Asociación de Hemato-Oncología Pediátrica de Centro América (AHOPCA): a model for sustainable development in pediatric oncology. Pediatr Blood Cancer (2013) 2.23
Familial adenomatous polyposis. Orphanet J Rare Dis (2009) 2.21
Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood (2004) 2.19
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood (2011) 2.18
Bone morphogenetic protein (BMP)-responsive elements located in the proximal and distal hepcidin promoter are critical for its response to HJV/BMP/SMAD. J Mol Med (Berl) (2009) 2.15
Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol (2003) 2.12
Pegylated interferon-α induced hypoferremia is associated with the immediate response to treatment in hepatitis C. Hepatology (2012) 2.12
Single-cell mutational profiling and clonal phylogeny in cancer. Genome Res (2013) 2.10
Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood (2006) 2.10
NMD: RNA biology meets human genetic medicine. Biochem J (2010) 2.09
Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years. Br J Haematol (2014) 2.07
Adult medulloblastoma comprises three major molecular variants. J Clin Oncol (2011) 2.07
Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood (2006) 2.06